Can radiation-recall predict long lasting response to immune checkpoint inhibitors?

被引：8

作者：

Deutsch, Eric ^{[1
,2
,3
]}

Besse, Benjamin ^{[2
,4
]}

Le Pavec, Jerome ^{[2
,5
]}

Le Pechoux, Cecile ^{[1
]}

Botticella, Angela ^{[1
]}

Ammari, Samy ^{[6
]}

Even, Caroline ^{[4
]}

Robert, Caroline ^{[2
,4
]}

Levy, Antonin ^{[1
,2
,3
]}

机构：

[1] Gustave Roussy, Inst Oncol Thorac IOT, Dept Radiat Oncol, Villejuif, France

[2] Univ Paris Saclay, Le Kremlin Bicetre, France

[3] Univ Paris Saclay, Gustave Roussy, INSERM U1030, Mol Radiotherapy, Villejuif, France

[4] Gustave Roussy, Dept Med Oncol, Inst Oncol Thorac IOT, Villejuif, France

[5] Hop Marie Lannelongue, Inst Oncol Thorac IOT, Serv Chirurg Thorac Vasc & Transplantat Cardiopul, Le Plessis Robinson, France

[6] Gustave Roussy, Dept Radiol, Villejuif, France

来源：

RADIOTHERAPY AND ONCOLOGY | 2021年 / 154卷

关键词：

Anti-PD1; Anti PD-L1; Anti CTLA4; Radioimmunotherapy;

D O I：

10.1016/j.radonc.2020.09.037

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

RR secondary to ICI (nivolumab in all patients) were observed in the lung (n = 1) or skin (n = 3). All patients had a long-term response to ICI and are currently alive with no active disease (Median FU from ICI discontinuation: 30 months). RR could reflect a beneficial immune activation and constitute a predictive clinical biomarker of ICI long-term efficacy. (C) 2020 Elsevier B.V. All rights reserved.

引用

页码：125 / 127

页数：3

共 19 条

[1] Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial [J].

Ascierto, Paolo A. ;

Long, Georgina V. ;

Robert, Caroline ;

Brady, Benjamin ;

Dutriaux, Caroline ;

Di Giacomo, Anna Maria ;

Mortier, Laurent ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Kalinka-Warzocha, Ewa ;

Savage, Kerry J. ;

Hernberg, Micaela M. ;

Lebbe, Celeste ;

Charles, Julie ;

Mihalcioiu, Catalin ;

Chiarion-Sileni, Vanna ;

Mauch, Cornelia ;

Cognetti, Francesco ;

Ny, Lars ;

Arance, Ana ;

Svane, Inge Marie ;

Schadendorf, Dirk ;

Gogas, Helen ;

Saci, Abdel ;

Jiang, Joel ;

Rizzo, Jasmine ;

Atkinson, Victoria .

JAMA ONCOLOGY, 2019, 5 (02) :187-194

[2] Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect? [J].

Bourgier, C. ;

Massard, C. ;

Moldovan, C. ;

Soria, J. -C. ;

Deutsch, E. .

ANNALS OF ONCOLOGY, 2011, 22 (02) :485-U269

[3] Vemurafenib and Radiosensitization [J].

Boussemart, Lise ;

Boivin, Catherine ;

Claveau, Joel ;

Tao, Yun Gan ;

Tomasic, Gorana ;

Routier, Emilie ;

Mateus, Christine ;

Deutsch, Eric ;

Robert, Caroline .

JAMA DERMATOLOGY, 2013, 149 (07) :855-857

[4] Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response? [J].

Davies, Michael A. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15) :1645-+

[5] Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial [J].

Eggermont, Alexander M. M. ;

Kicinski, Michal ;

Blank, Christian U. ;

Mandala, Mario ;

Long, Georgina V. ;

Atkinson, Victoria ;

Dalle, Stephane ;

Haydon, Andrew ;

Khattak, Adnan ;

Carlino, Matteo S. ;

Sandhu, Shahneen ;

Larkin, James ;

Puig, Susana ;

Ascierto, Paolo A. ;

Rutkowski, Piotr ;

Schadendorf, Dirk ;

Koornstra, Rutger ;

Hernandez-Aya, Leonel ;

Di Giacomo, Anna Maria ;

van den Eertwegh, Alfonsus J. M. ;

Grob, Jean-Jacques ;

Gutzmer, Ralf ;

Jamal, Rahima ;

Lorigan, Paul C. ;

Krepler, Clemens ;

Ibrahim, Nageatte ;

Marreaud, Sandrine ;

van Akkooi, Alexander ;

Robert, Caroline ;

Suciu, Stefan .

JAMA ONCOLOGY, 2020, 6 (04) :519-527

[6] Inflammation Flare and Radiation Necrosis Around a Stereotactic Radiotherapy-Pretreated Brain Metastasis Site After Nivolumab Treatment [J].

Furuta, Hiromi ;

Yoshida, Tatsuya ;

Natsume, Atsushi ;

Hida, Toyoaki ;

Yatabe, Yasushi .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) :1975-1978

[7] Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-Small Cell Lung Cancer [J].

Furuta, Hiromi ;

Yoshida, Tatsuya ;

Shimizu, Junichi ;

Tomita, Natsuo ;

Yatabe, Yasushi ;

Hida, Toyoaki .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :1733-1736

[8] Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer [J].

Greally, Megan ;

Chou, Joanne F. ;

Chatila, Walid K. ;

Margolis, Matthew ;

Capanu, Marinela ;

Hechtman, Jaclyn F. ;

Tuvy, Yaelle ;

Kundra, Ritika ;

Daian, Foysal ;

Ladanyi, Marc ;

Kelsen, David P. ;

Ilson, David H. ;

Berger, Michael F. ;

Tang, Laura H. ;

Solit, David B. ;

Diaz, Luis A., Jr. ;

Schultz, Nikolaus ;

Janjigian, Yelena Y. ;

Ku, Geoffrey Y. .

CLINICAL CANCER RESEARCH, 2019, 25 (20) :6160-6169

[9] Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy [J].

Haraldsdottir, Sigurdis ;

Bertino, Erin ;

Haglund, Karl ;

Kaffenberger, Benjamin ;

Shah, Manisha H. .

JAMA DERMATOLOGY, 2016, 152 (05) :587-589

[10] Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial [J].

Harrington, Kevin J. ;

Ferris, Robert L. ;

Blumenschein, George, Jr. ;

Colevas, A. Dimitrios ;

Fayette, Jerome ;

Licitra, Lisa ;

Kasper, Stefan ;

Even, Caroline ;

Vokes, Everett E. ;

Worden, Francis ;

Saba, Nabil F. ;

Kiyota, Naomi ;

Haddad, Robert ;

Tahara, Makoto ;

Gruenwald, Viktor ;

Shaw, James W. ;

Monga, Manish ;

Lynch, Mark ;

Taylor, Fiona ;

DeRosa, Michael ;

Morrissey, Laura ;

Cocks, Kim ;

Gillison, Maura L. ;

Guigay, Joel .

LANCET ONCOLOGY, 2017, 18 (08) :1104-1115

← 1 2 →